涉嫌误导性陈述 亚辉龙遭证监会立案调查

Core Viewpoint - The company Aihuilong (688575.SH) is under investigation by the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure laws, which has led to a decline in its stock price and raised concerns about its strategic partnership with Brain Machine Star Chain Technology Co., Ltd. [1][5] Group 1: Investigation and Stock Impact - On February 6, Aihuilong received a notice from the CSRC regarding an investigation due to misleading statements related to a strategic cooperation framework agreement signed with Brain Machine Star Chain [1][5] - Following the announcement of the partnership, Aihuilong's stock price fell by 2.98% to 14.02 yuan per share, with a significant increase in trading volume [1][3] - The Shanghai Stock Exchange issued a regulatory warning to Aihuilong, emphasizing the need for accurate and complete information disclosure, especially given the market's heightened interest in brain-machine interface technology [3][4] Group 2: Business Operations and Financial Forecast - Aihuilong's main business involves the research, production, and sales of in vitro diagnostic instruments and related reagents, covering various medical fields [6] - The company expects a significant decline in net profit for 2025, projecting a decrease of approximately 90.05% to 93.37% compared to 2024, with net profit estimated between 20 million to 30 million yuan [6][7] - The decline in profit is attributed to reduced domestic market demand due to industry policies, leading to decreased revenue and gross margin [6][7] Group 3: Strategic Partnership Details - Aihuilong announced a strategic partnership with Brain Machine Star Chain to develop brain-machine interface products, focusing on non-invasive technology [4] - The estimated investment for the collaboration is around 30 million yuan, with Aihuilong's investment not exceeding 15 million yuan [4] - Brain Machine Star Chain, established in September 2025, has a registered capital of 5 million yuan and claims to focus on both non-invasive and invasive brain-machine interface technologies [4]